OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MORISON50

Morison Industries PLC

PharmaceuticalsVerified

Morison Industries has a fully diluted share count of 1.256 billion shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the valuation snapshot, and no industry-specific preferred metrics are provided in the industry configuration. Without comparative data, it is not possible to assess Morison's profitability or returns relative to its peers. Segment and geographic exposure data are not disclosed in the available financials, making it impossible to determine revenue concentration or geographic diversification. Growth trajectory is not quantified in the outlook, and no numeric deltas are provided for the current or next fiscal year. Historical revenue data is also not available in the input, preventing a detailed growth analysis. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. No dilution risk is currently flagged, but the absence of balance-sheet data limits the ability to evaluate capital structure stability. Recent events, including filings or transcripts, are not disclosed in the input data, so no specific developments can be reported.

30-day price · MORISON-0.38 (-3.5%)
Low$10.62High$11.79Close$10.62As of29 Apr, 00:00 UTC
Profile
CompanyMorison Industries PLC
TickerMORISON.LG
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

Morison Industries has a fully diluted share count of 1.256 billion shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the valuation snapshot, and no industry-specific preferred metrics are provided in the industry configuration. Without comparative data, it is not possible to assess Morison's profitability or returns relative to its peers. Segment and geographic exposure data are not disclosed in the available financials, making it impossible to determine revenue concentration or geographic diversification. Growth trajectory is not quantified in the outlook, and no numeric deltas are provided for the current or next fiscal year. Historical revenue data is also not available in the input, preventing a detailed growth analysis. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. No dilution risk is currently flagged, but the absence of balance-sheet data limits the ability to evaluate capital structure stability. Recent events, including filings or transcripts, are not disclosed in the input data, so no specific developments can be reported.
Key takeaways
  • Morison Industries has no dilution risk as of the latest data, with basic and diluted shares outstanding being equal.
  • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • No profitability or returns data is available for comparison with industry peers.
  • Growth trajectory and revenue history are not quantified in the available data.
  • Segment and geographic exposure details are not disclosed, limiting visibility into revenue concentration.
  • --
  • **RATIONALES**:
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4
FY-3
FY-2
FY-1
FY0
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4
FY-3
FY-2
FY-1
FY0
PeriodOCFCapExFCFSBC
FY-4
FY-3
FY-2
FY-1
FY0
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricMORISONActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity9.3% medp25 0.1% · p75 43.8%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 01:16 UTC#6800672f
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 15:18 UTCJob: cb336553